Treatment with TH37 significantly inhibited the colony formation of primary CD34 + AML cells, while showing no significant effects on normal CD34+ hematopoietic stem and progenitor cells (HSPCs) (Fig. 1B, C). The gene discussed is CD34; the disease is acute myeloid leukemia.